Short Summary
Curio Bioscience petitions the PTAB to invalidate claims of U.S. Patent 11,549,138 covering spatially encoded biological assays, arguing obviousness over Cantor and Armani and anticipation by Frisen, and asserting lack of written description support.
Detailed Summary
In Petition IPR2025-00192, Curio Bioscience, Inc. challenges seven claims of U.S. Patent No. 11,549,138, which it alleges are directed to conventional nucleic acid array technologies. The petitioner asserts that the claims are obvious in view of Cantor’s 2009 bead array disclosures, especially when combined with the knowledge of a person of ordinary skill in the art (POSA), and further obvious over Cantor when combined with Armani’s 2009 2D‑PCR methods. Additionally, Curio contends that the claims are anticipated by Frisen’s 2014 spatially barcoded array application. The petition also argues that the specification lacks written description support for the claimed inventions and that there is no basis for discretionary denial under §§314(a) or 325(d). The Board is asked to institute the IPR and cancel the challenged claims.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Curio Bioscience, Inc. vs Prognosys Biosciences Inc. et al. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Abbott Diabetes Care Inc. et al.vsDexCom, Inc.
Abbott Diabetes Care Inc. has filed a petition challenging DexCom’s '031 patent related to Continuous Glucose Monitoring (CGM) technology. The challenge asserts that the core inventive feature—using prior information to manage sensor sensitivity drift—is anticipated or rendered obvious by existing prior art references, Zhang and Shin.
Berkshire Hathaway Energy Company et al.vsMES, Inc.
Berkshire Hathaway’s energy affiliates and patent owner Birchtech have settled their dispute over U.S. Patent 10,596,517. The parties filed a joint motion to terminate the IPR as to MidAmerican, citing settlement and lack of a merits decision.
Samsung Electronics Co., Ltd. et al.vsSiOnyx, LLC
Samsung and SiOnyx have settled their dispute over U.S. Patent 9,905,599 and jointly moved to terminate the inter partes review, requesting the settlement be kept confidential.
Zhuhai CosMX Battery Co., Ltd.vsNingde Amperex Technology Ltd.
CosMX seeks Director Review to overturn the Board’s decision instituting an IPR on Ningde’s battery patent. The request argues that conflicting claim constructions in two parallel petitions require denial under the Director’s guidance and discretionary authority.
Advanced Micro Devices, Inc. et al.vsXtreamEdge, Inc. et al.
AMD and Pensando seek to invalidate XtreamEdge’s network‑optimization patent, but the patent owners argue the cited prior art fails to disclose a key bandwidth limitation, prompting a request for discretionary denial of institution.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.